Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,186 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cost-utility analysis of molnupiravir for high-risk, community-based adults with COVID-19: an economic evaluation of the PANORAMIC trial.
Png ME, Harris V, Grabey J, Hart ND, Jani BD, Butler D, Carson-Stevens A, Coates M, Cureton L, Dobson M, Dorward J, Evans P, Francis N, Gbinigie OA, Hayward G, Holmes J, Hood K, Khoo S, Ahmed H, Lown M, McKenna M, Mort S, Nguyen-Van-Tam JS, Rahman NM, Richards DB, Thomas NP, van Hecke O, Hobbs R, Little P, Yu LM, Butler CC, Petrou S; PANORAMIC Trial Collaborators. Png ME, et al. Among authors: khoo s. Br J Gen Pract. 2024 Jul 25;74(745):e570-e579. doi: 10.3399/BJGP.2023.0444. Print 2024 Aug. Br J Gen Pract. 2024. PMID: 38228357 Free PMC article.
Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe disease.
Gbinigie O, Ogburn E, Allen J, Dorward J, Dobson M, Madden TA, Yu LM, Lowe DM, Rahman N, Petrou S, Richards D, Hood K, Patel M, Saville BR, Marion J, Holmes J, Png ME, Hayward G, Lown M, Harris V, Jani B, Hart N, Khoo S, Rutter H, Chalk J, Standing JF, Breuer J, Lavallee L, Hadley E, Cureton L, Benysek M, Andersson MI, Francis N, Thomas NPB, Evans P, van Hecke O, Koshkouei M, Coates M, Barrett S, Bateman C, Davies J, Raymundo-Wood I, Ustianowski A, Nguyen-Van-Tam J, Carson-Stevens A, Hobbs R, Little P, Butler CC. Gbinigie O, et al. Among authors: khoo s. BMJ Open. 2023 Aug 7;13(8):e069176. doi: 10.1136/bmjopen-2022-069176. BMJ Open. 2023. PMID: 37550022 Free PMC article.
Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trial.
Harris V, Holmes J, Gbinigie-Thompson O, Rahman NM, Richards DB, Hayward G, Dorward J, Lowe DM, Standing JF, Breuer J, Khoo S, Petrou S, Hood K, Ahmed H, Carson-Stevens A, Nguyen-Van-Tam JS, Patel MG, Saville BR, Francis N, Thomas NPB, Evans P, Dobson M, Png ME, Lown M, van Hecke O, Jani BD, Hart ND, Butler D, Cureton L, Patil M, Andersson M, Coates M, Bateman C, Davies JC, Raymundo-Wood I, Ustianowski A, Yu LM, Hobbs FDR, Little P, Butler CC; PANORAMIC Trial Collaborative Group. Harris V, et al. Among authors: khoo s. Lancet Infect Dis. 2024 Sep 9:S1473-3099(24)00431-6. doi: 10.1016/S1473-3099(24)00431-6. Online ahead of print. Lancet Infect Dis. 2024. PMID: 39265595 Free article.
Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial.
Donovan-Banfield I, Penrice-Randal R, Goldswain H, Rzeszutek AM, Pilgrim J, Bullock K, Saunders G, Northey J, Dong X, Ryan Y, Reynolds H, Tetlow M, Walker LE, FitzGerald R, Hale C, Lyon R, Woods C, Ahmad S, Hadjiyiannakis D, Periselneris J, Knox E, Middleton C, Lavelle-Langham L, Shaw V, Greenhalf W, Edwards T, Lalloo DG, Edwards CJ, Darby AC, Carroll MW, Griffiths G, Khoo SH, Hiscox JA, Fletcher T. Donovan-Banfield I, et al. Among authors: khoo sh. Nat Commun. 2022 Nov 26;13(1):7284. doi: 10.1038/s41467-022-34839-9. Nat Commun. 2022. PMID: 36435798 Free PMC article. Clinical Trial.
Monkeypox virus isolation from longitudinal samples in 11 hospitalised patients.
Callaby H, Olver J, Emery K, Richards KS, Killip M, Groves N, Beadsworth MBJ, Price DA, Cooke GS, Collini P, Cole J, Dunning J, Semple MG, Baillie JK; ISARIC4C Investigators; Rampling T, Houlihan CF. Callaby H, et al. Lancet Infect Dis. 2024 Nov 28:S1473-3099(24)00735-7. doi: 10.1016/S1473-3099(24)00735-7. Online ahead of print. Lancet Infect Dis. 2024. PMID: 39617024 No abstract available.
SARS-CoV-2 cross-sectional serosurvey across three HIV-1 therapeutic clinical trials in Africa.
Papot E, Tovar-Sanchez T, Woods J, Thaurignac G, Eriobu N, Borok M, Kaplan R, Avihingsanon A, Azwa I, Grinsztejng B, Kumarasamy N, Sokhela S, Mpoudi-Etame M, Arriaga M, Jacoby S, Matthews GV, Losso MH, Khoo S, Calmy A, Kouanfack C, Ayouba A, Petoumenos K, Venter WDF, Delaporte E, Polizzotto MN; COHIVE study group (COHIVE consortium includes ADVANCE, DolPHIN2, D2EFT and NAMSAL study groups). Papot E, et al. Among authors: khoo s. AIDS. 2024 Nov 22. doi: 10.1097/QAD.0000000000004068. Online ahead of print. AIDS. 2024. PMID: 39576151
1,186 results